AbbVie's Aquipta/Qulipta approved by EC to prevent migraine
US drugmaker AbbVie (NYSE: ABBV) has won approval from the European Commission (EC) for Aquipta (atogepant) for the prophylaxis of migraine in adults who have four or more migraine days per month.
The approval makes Aquipta, which is branded in North America as Qulipta, the first and only once-daily oral calcitonin gene-related peptide (CGRP) receptor antagonist treatment in the European Union for the preventive treatment of both chronic and episodic migraine.
This approval gives further credibility to AbbVie’s stated ambitions to be a leader in the treatment of migraine. Botox (onabotulinumtoxinA) is AbbVie’s foundational, first US Food and Drug Administration-approved preventive treatment for chronic migraine, and Ubrelvy (ubrogepant), an acute treatment for migraine attacks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze